A Study of Zidovudine Plus Acyclovir in HIV-Infected Patients
Status:
Completed
Trial end date:
1990-10-01
Target enrollment:
Participant gender:
Summary
To compare the effect of zidovudine (AZT) given alone with the combination of AZT and
acyclovir (ACV) on the human immunodeficiency virus (HIV) in persons infected with HIV, and
to study the pharmacokinetics (how fast AZT reaches certain levels in blood and how long it
remains), safety, and effectiveness of AZT given alone and in combination with ACV in
treating HIV-infected patients. Other studies have shown that AZT offers potential benefits
to specific AIDS patients when given over long time periods, and experiments in vitro (in the
test tube) suggest that ACV may stimulate the action of AZT against HIV. It is necessary to
obtain information on how these drugs perform in HIV-infected humans.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)